neuroleptic malignant syndrome

Neuroleptic malignant syndrome (NMS) is a rare, life-threatening reaction to drugs that block dopamine signalling in the brain, most commonly antipsychotics. It is characterised by the convergence of severe muscle rigidity, dangerously elevated body temperature, and collapse of normal autonomic regulation — the network of unconscious processes that governs heart rate, blood pressure, and sweating.

The condition can develop within hours of starting or increasing a drug, though it sometimes takes days to appear. It is considered a medical emergency. Despite the word neuroleptic in its name — an older term for antipsychotic — it is not limited to psychiatric contexts and can arise wherever strong dopamine blockade occurs.

How it works · its role

The underlying mechanism is thought to involve sudden, widespread blockade of dopamine D2 receptors in several brain regions simultaneously. In the hypothalamus, dopamine helps regulate core body temperature; when that signal is disrupted, temperature control can fail catastrophically, driving fever.

In the striatum, loss of dopamine tone removes the brake on motor pathways, producing the lead-pipe rigidity that is one of NMS's most recognisable signs. Autonomic instability — fluctuating blood pressure, rapid heart rate, profuse sweating — is thought to reflect dopamine blockade in the spinal cord and brainstem circuits that coordinate those functions.

The sustained muscle contraction also causes widespread breakdown of muscle tissue, releasing proteins into the bloodstream that can damage the kidneys — a secondary complication that worsens the overall picture.

Relevance to substances & effects

Antipsychotic drugs are the most common trigger. Both older typical antipsychotics — such as haloperidol and chlorpromazine — and newer atypical antipsychotics carry the risk, though the syndrome appears to be somewhat less frequent with atypicals.

Other dopamine-blocking agents used outside psychiatry, including some antiemetics, can also precipitate NMS. In a related pattern, abrupt withdrawal from dopaminergic drugs — medications that supplement dopamine rather than block it — is sometimes associated with a clinically similar syndrome, suggesting the mechanism runs in both directions.

Dehydration, physical agitation, and rapid dose escalation are considered to increase risk across substance classes that affect dopamine pathways.

Clinical · risk note

The four cardinal signs that point toward NMS are hyperthermia, generalised muscle rigidity, altered or fluctuating mental status, and autonomic instability. No single sign is sufficient on its own, and the condition can be mistaken for an infection, another drug reaction, or a primary neurological event.

A markedly elevated creatine kinase level — a blood marker of muscle breakdown — is a key supporting finding and helps distinguish NMS from similar-looking conditions such as serotonin syndrome, which has a different mechanism and a different pattern of muscle findings.

The first step in treatment is stopping the causative drug as quickly as is safely possible. Intensive supportive care follows, and in some cases specific pharmacological agents are used to restore dopamine activity or reduce muscle contraction. With prompt recognition, outcomes have improved considerably; delays in identifying the syndrome are the primary driver of serious harm.